STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] QHSLab, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

QHSLab, Inc. (USAQ) filed an 8-K to furnish a shareholder letter under Regulation FD. On November 24, 2025, the company reported that it sent a letter to its shareholders, which is attached as Exhibit 99.1. The information in this exhibit is furnished under Item 7.01, meaning it is not considered “filed” for liability purposes under Section 18 of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.

The company reiterates that it has no obligation to update forward-looking statements. It also highlights that investors, media, and others may receive material information through its website (usaqcorp.com), press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.

Positive

  • None.

Negative

  • None.
false 0000856984 0000856984 2025-11-24 2025-11-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): November 24, 2025

 

QHSLab, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

0-19041

(Commission File No.)

 

Nevada   30-1104301

(State

of Incorporation)

 

(I.R.S. Employer

Identification No.)

     

901 Northpoint Parkway Suite 302 West Palm Beach

FL 33407

  33407
(Address of Principal Executive Offices)   (ZIP Code)

 

Registrant’s telephone number, including area code: (929) 379-6503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   USAQ   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On November 24, 2025, QHSLab, Inc. (the “Company”), sent a letter to its shareholders, a copy of which is attached as Exhibit 99.1.

 

The information in the press release annexed as Exhibit 99.1 to this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

 

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

 

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/), Facebook account (https://www.facebook.com/QHSLabs) and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

 

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits.

 

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

 

Exhibit No.   Description
99.1   Letter to shareholders dated November 24, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 24, 2025  
     
QHSLab, Inc.  
     
  /s/ Troy Grogan  
Name: Troy Grogan  
Title: CEO and Chairman  

 

 

FAQ

What did QHSLab (USAQ) report in its November 24, 2025 8-K?

QHSLab, Inc. reported that on November 24, 2025 it sent a letter to shareholders, which is attached as Exhibit 99.1 and furnished under Item 7.01 (Regulation FD Disclosure).

What is Exhibit 99.1 in QHSLab’s USAQ 8-K filing?

Exhibit 99.1 is a letter to shareholders dated November 24, 2025 that QHSLab, Inc. furnished as part of its 8-K under Item 7.01 Regulation FD Disclosure.

Is the shareholder letter in QHSLab’s 8-K considered filed with the SEC?

No. The shareholder letter in Exhibit 99.1 is furnished, not filed, and is therefore not subject to Section 18 liabilities or automatically incorporated into other Exchange Act or Securities Act filings unless specifically referenced.

How does QHSLab (USAQ) distribute material information to investors?

QHSLab states that it uses its website (usaqcorp.com), press releases, and social media channels including Twitter, LinkedIn, Facebook, and Instagram as additional means of disclosing public information, which could be deemed material.

What caution does QHSLab give about forward-looking statements in this 8-K?

QHSLab states that it does not have and expressly disclaims any obligation to publicly update forward-looking statements or changes in events, conditions, or circumstances on which such statements are based.

Which Item of Form 8-K does QHSLab use for this disclosure?

QHSLab uses Item 7.01, Regulation FD Disclosure, indicating the shareholder letter is provided to keep the market informed under fair disclosure principles rather than as a filed, liability-bearing report.
QHSLab Inc

OTC:USAQ

USAQ Rankings

USAQ Latest News

USAQ Latest SEC Filings

USAQ Stock Data

1.81M
7.44M
34.07%
12.66%
Medical Devices
Healthcare
Link
United States
West Palm Beach